BI 3031185 clinical trials
Also written BI 3031185.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2024
How each study uses BI 3031185 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 3031185
- 5
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BI 3031185 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and WomenSuspendedPhase 1Boehringer IngelheimNCT06916702Written as BI 3031185
- A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the BloodTerminatedPhase 1Boehringer IngelheimNCT07656792Written as BI 3031185
- A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity DisorderCompletedPhase 1Boehringer IngelheimNCT07001475Written as BI 3031185
- A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the BloodCompletedPhase 1Boehringer IngelheimNCT07211425Written as BI 3031185
- A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the BloodCompletedPhase 1Boehringer IngelheimNCT06255340Written as BI 3031185